HCWBライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:44):

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases...

Stats
本日の出来高	1 204.00
平均出来高	15 712.00
時価総額	55.22M
EPS	$-0.300 ( 2024-04-01 )
次の収益日	( $0 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.09
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-20	Wong Hing C	Buy	739 288	Common Stock
2024-02-20	Greene Rick S.	Buy	35 714	Common Stock
2024-02-20	Giles Lisa M.	Buy	35 715	Common Stock
2024-02-20	Garrett Scott T	Buy	142 858	Common Stock
2024-02-20	Flowers Lee	Buy	71 429	Common Stock

INSIDER POWER
92.27
Last 100 transactions
Buy: 3 866 595 \| Sell: 3 743 515

HCW Biologics Inc. 相関

10 最も正の相関
CEG	0.899
CSSEP	0.897
CYRN	0.896
BIMI	0.892
FCBC	0.891
IRBT	0.889
DRUG	0.888
JAGX	0.888
CZNC	0.887
CSSE	0.878

10 最も負の相関
BCOR	-0.917
AMTBB	-0.905
TZPS	-0.903
GLLI	-0.899
ARYD	-0.895
LCYAU	-0.894
MCAA	-0.893
EBACU	-0.892
SVFA	-0.89
TMKR	-0.888

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

HCW Biologics Inc. 財務諸表

Annual	2023
収益:	$2.84M
総利益:	$-574 824 (-20.23 %)
EPS:	$-0.700

FY	2023
収益:	$2.84M
総利益:	$-574 824 (-20.23 %)
EPS:	$-0.700

FY	2022
収益:	$6.72M
総利益:	$2.59M (38.48 %)
EPS:	$-0.410

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.527

Financial Reports:

No articles found.

HCW Biologics Inc.

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.